Bacterial Vaginosis Market

Market Overview:

The 7 major bacterial vaginosis markets reached a value of US$ 762.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,405.4 Million by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.

The bacterial vaginosis market has been comprehensively analyzed in IMARC's new report titled "Bacterial Vaginosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial vaginosis is a form of vaginal infection caused by an overgrowth of the normally occurring bacteria in the vagina. The disease is triggered by a reduction in the amount of typical hydrogen peroxide-producing lactobacilli (good bacteria), along with an increase in anaerobic (bad) bacteria. This results in an imbalance of bacterial flora within the vagina, which can even raise the likelihood of sexually transmitted infections among patients. Many women with bacterial vaginosis have no signs or symptoms. In other cases, the common indications of the ailment include thin, gray, green, or white vaginal discharge; a foul-smelling, fishy vaginal odor; itching; irritation; a burning sensation during urination, etc. The diagnosis of this illness typically requires a combination of the underlying symptoms, medical history, and a physical test. The healthcare professional may perform a pelvic exam to determine the characteristics of the vaginal discharge and to rule out other possible causes. Some of the frequently used diagnostic workups include gram staining of vaginal secretions, presence of clue cells on wet mount, whiff test, etc.

The increasing utilization of vaginal douches or feminine hygiene products, which can disrupt the normal bacterial balance in the vagina, is primarily driving the bacterial vaginosis market. In addition to this, the rising incidence of several associated risk factors, such as multiple sexual partners, unprotected sex, cigarette smoking, use of an intrauterine device, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nitroimidazole antimicrobials and lincosamide antibiotics to destroy or stop the proliferation of bacteria causing the condition is acting as another significant growth-inducing factor. Apart from this, the inflating application of lactobacillus colonization therapy, which aims to boost the number of good bacteria in the vagina and re-establish a stabilized vaginal environment in patients, is further creating a positive outlook for the market. Additionally, the ongoing development of intravaginal anti-infective boric acid enhanced with ethylenediaminetetraacetic acid (EDTA) for treating the ailment since they can improve activity against harmful bacteria while protecting the beneficial lactobacilli is expected to drive the bacterial vaginosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bacterial vaginosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bacterial vaginosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial vaginosis market in any manner.

Recent Developments:

• In November 2023, Inflammatix, Inc., announced that it had completed technical development for its TriVerity Acute Infection and Sepsis Test System, which consists of the Myrna Instrument, as well as the TriVerity Cartridge. TriVerity is designed to be utilized in emergency department settings in patients with suspected acute infection and sepsis to determine the likelihood of a bacterial infection and the risk of acute decompensation (requiring ICU-level care).

Key Highlights:

• Bacterial vaginosis is the most common vaginitis in reproductive-aged women, with a prevalence estimated to be between 5% and 70%.
• The prevalence of bacterial vaginosis among females varies between 20% and 60% across different countries.
• This condition is most widespread in portions of Africa, with the lowest prevalence reported in Asia and Europe.
• In the United States, bacterial vaginosis rates are around 30%.
• In non-white women, rates are highest (51% in African American women and 32% in Mexican American women), although they vary across ethnic groups.

Drugs:

Nuvessa (metronidazole vaginal gel 1.3%) is a nitroimidazole antimicrobial prescribed for the treatment of bacterial vaginosis in girls aged 12 and above. The medication comes in a prefilled, single-dose disposable applicator. Each applicator contains roughly 65 milligrams of metronidazole in 5 g of vaginal gel.

LACTIN-V is being developed to prevent recurrent bacterial vaginosis. It contains Lactobacillus crispatus CTV-05, a single strain of vaginal Lactobacillus that produces hydrogen peroxide and is found naturally in the vaginal microbiome of many healthy women. It was chosen for qualities that improve vaginal microbiome, prevent urogenital infections, and boost reproductive health.

TOL-463 is an anti-infective drug being developed for the treatment of bacterial vaginosis. It is a boric acid-based vaginal anti-infective augmented with ethylenediaminetetraacetic acid (EDTA), which was developed to have better effectiveness against vaginal bacterial and fungal biofilms while sparing protecting lactobacilli.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bacterial vaginosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bacterial vaginosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bacterial vaginosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bacterial vaginosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bacterial vaginosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bacterial vaginosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bacterial vaginosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bacterial vaginosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bacterial vaginosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with bacterial vaginosis across the seven major markets?
• What is the size of the bacterial vaginosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bacterial vaginosis?
• What will be the growth rate of patients across the seven major markets?
   

Bacterial Vaginosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bacterial vaginosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial vaginosis market?
• What are the key regulatory events related to the bacterial vaginosis market?
• What is the structure of clinical trial landscape by status related to the bacterial vaginosis market?
• What is the structure of clinical trial landscape by phase related to the bacterial vaginosis market?
• What is the structure of clinical trial landscape by route of administration related to the bacterial vaginosis market?